Gilead Sciences, Inc. (GILD) — closed signal from November 1, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 30, 2026.
Predicted vs. what happened
What happened
Reached its target in 83 days.
The thesis — published November 1, 2025
Shares slipped after the third-quarter report even though profit and sales beat expectations, led by HIV and liver medicines. The drop looks overdone and may bounce back over the next 1 to 3 months as worries about the cancer business calm down. Early headlines drove a quick sell-first reaction, but attitudes often settle. Strong cash flow and a steady core lineup help limit downside while the market reassesses.
Primary drivers
- Quarter beat estimates; HIV and liver drugs drove solid sales growth
- Stock looks washed out; recent average price trend is improving
- Cancer-drug concerns are easing as the market absorbs the news
- Many more trades than usual hint at interest and a near-term opportunity
How it played out
GILD: target reached in 83 days
Lyra published GILD at $119 on 2025-11-01 with a short-term thesis for 13% growth. The thesis pointed to a third-quarter beat, solid HIV and liver medicine sales, an improving recent price trend, easing concern around the cancer business, heavier trading, strong cash flow, and a steady core lineup.
Inside the window, the stock reached the $133.59 target after 83 days. It peaked at $142.20 on 2026-01-30, with a 19.5% gain, and ended at $141.95. The published rebound thesis played out fully by the numbers.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.